Literature DB >> 11152434

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

E Cercenado1, F García-Garrote, E Bouza.   

Abstract

The in vitro activity of the oxazolidinone linezolid was compared with the activities of vancomycin and teicoplanin against 450 Gram-positive clinical isolates, including a variety of multiply resistant strains. Linezolid inhibited all microorganisms tested at < or = 4 mg/L, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci and viridans streptococci, and erythromycin-resistant beta-haemolytic streptococci. The MIC(90) of linezolid for all isolates was 2 mg/L.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152434     DOI: 10.1093/jac/47.1.77

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  In vitro activity of linezolid against Clostridium difficile.

Authors:  T Peláez; R Alonso; C Pérez; L Alcalá; O Cuevas; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Antistaphylococcal activity of DX-619 alone and in combination with vancomycin, teicoplanin, and linezolid assessed by time-kill synergy testing.

Authors:  Kim Credito; Genrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

Review 4.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Antipneumococcal activity of dalbavancin compared to other agents.

Authors:  Gengrong Lin; Kathy Smith; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Lois M Ednie; Glenn Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.

Authors:  Dianne B Hoellman; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.